1. Schmelzer J, Dugan E, Blach S, et al. Global prevalence of hepatitis C virus in children in 2018: a modelling study. Lancet Gastroenterol Hepatol 2020; 5: 374-392.
2.
Indolfi G, Easterbrook P, Dusheiko G, et al. Hepatitis C virus infection in children and adolescents. Lancet Gastroenterol Hepatol 2019; 4: 477-487.
3.
Modin L, Arshad A, Wilkes B, et al. Epidemiology and natural history of hepatitis C virus infection among children and young people. J Hepatol 2019; 70: 371-378.
4.
Pokorska-Śpiewak M, Dobrzeniecka A, Lipińska M, et al. Liver fibrosis evaluated with transient elastography in 35 children with chronic hepatitis C virus infection. Pediatr Infect Dis J 2021; 40: 103-108.
5.
WHO. Updated recommendations on treatment of adolescents and children with chronic HCV infection: Policy brief. Geneva 2022.
6.
Brigham D, Narkewicz MR. Profile of sofosbuvir and velpatasvir combination in the treatment of chronic hepatitis C in children and adolescents: Current evidence. Ther Clin Risk Manag 2024; 20: 1-7.
7.
Indolfi G, Easterbrook P, Giometto S, et al. Efficacy and safety of DAA in children and adolescents with chronic HCV infection: A systematic review and meta-analysis. Liver Int 2024; 44: 663-681.
8.
Jonas MM, Romero R, Rosenthal P, et al. Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2024; 78: 1342-1354.
9.
Pokorska-Śpiewak M, Talarek E, Aniszewska M, et al. Efficacy and safety of treatment with sofosbuvir/velpatasvir in patients aged 6-18 years with chronic hepatitis C – results of the PANDAA-PED study. Liver Int 2023; 49: 1871-1878.
10.
Castera L, Vergniol J, Foucher J, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-350.
11.
Mogahed EA, El-Karaksy H, Abdullatif H, et al. Improvement in liver stiffness in pediatric patients with hepatitis C virus after treatment with direct acting antivirals. J Pediatr 2021; 233: 126-131.
12.
Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol 2012; 36: 13-20.
13.
Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology (Baltimore, Md) 2006; 43: 1317-1325.
14.
Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
15.
Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology (Baltimore, Md) 2011; 53: 726-736.
16.
Pokorska-Śpiewak M, Dobrzeniecka A, Marczyńska M. One-year outcomes after ledipasvir/sofosbuvir treatment of chronic hepatitis C in teenagers with and without significant liver fibrosis – a case series report. Viruses 2021; 13: 1518.
17.
Fahmy DM, Shokeir M, El Zeiny SM, et al. Changes in liver stiffness and noninvasive fibrosis scores in Egyptian adolescents successfully treated with ledipasvir-sofosbuvir for chronic hepatitis C virus infection. J Pediatr 2021; 231: 110-116.
18.
Makhlouf NA, Abdelmalek MO, Ibrahim ME, et al. Ledipasvir/sofosbuvir in adolescents with chronic hepatitis C genotype 4 with and without hematological disorders: virological efficacy and impact on liver stiffness. J Pediatric Infect Dis Soc 2021; 10: 7-13.
19.
Trifan A, Stratina E, Rotaru A, et al. Changes in liver steatosis using controlled attenuation parameter among patients with chronic hepatitis C infection treated with direct-acting antivirals therapy who achieved sustained virological response. Diagnostics (Basel) 2022; 12: 702.
20.
Rout G, Nayak B, Patel AH, et al. Therapy with oral directly acting agents in hepatitis C infection is associated with reduction in fibrosis and increase in hepatic steatosis on transient elasto-
21.
graphy. J Clin Exp Hepatol 2019; 9: 207-214.
22.
Kawagishi N, Suda G, Nakamura A, et al. Liver steatosis and dyslipidemia after HCV eradication by direct acting antiviral agents are synergistic risks of atherosclerosis. PLoS One 2018; 13: e0209615.
23.
Tokuchi Y, Suda G, Kawagishi N, et al. Hepatitis C virus eradication by direct-acting antivirals causes a simultaneous increase in the prevalence of fatty liver and hyper low-density lipoprotein cholesterolemia without an increase in body weight. Hepatol Res 2023; 53: 595-606.
24.
Villani R, Di Cosimo F, Romano AD, et al. Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis. Sci Rep 2021; 11: 13944.
25.
Pokorska-Śpiewak M, Kowalik-Mikołajewska B, Aniszewska M, et al. Is liver biopsy still needed in children with chronic viral hepatitis? World J Gastroenterol 2015; 21: 12141-12149.
26.
de Ledinghen V, Le Bail B, Rebouissoux L, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007; 45: 443-450.
27.
Nobili V, Vizzutti F, Arena U, et al. Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology (Baltimore, Md) 2008; 48: 442-448.
Copyright: © Clinical and Experimental Hepatology. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/) enables reusers to distribute, remix, adapt, and build upon the material in any medium or format for noncommercial purposes only, and only so long as attribution is given to the creator. If you remix, adapt, or build upon the material, you must license the modified material under identical terms.
